Tromsø, Norway, 9th December 2022 – ArcticZymes Technologies ASA (OSE: AZT) upscales the production of ArcticZymes Proteinase and launches ArcticZymes Proteinase Glycerol FREE ArcticZymes Technologies (AZT) has successfully upscaled the production of ArcticZymes Proteinase. This will allow the Company to meet growing demand from new and existing customers, thereby strengthening the Company´s position as a supplier of critical components in …
Tromsø, Norway, 08th December 2022 – ArcticZymes Technologies ASA (OSE: AZT) exclusively licenses novel DNA assembly technology from UiT The Arctic University of Norway ArcticZymes Technologies (AZT) has signed an exclusive licensing agreement with UiT The Arctic University of Norway (UiT) for a novel DNA assembly technology. The technology was developed by researchers at UiT and is based on unique …
ArcticZymes Technologies is attending the MEDICA 2022 at the Messe Düsseldorf, Germany from 14-17 November. Kees Linschooten, Senior Business Development Manager, Helge Lind, Ph.D., Senior Market Development Manager, and Dirk Hahneiser VP of Business Development and Marketing are looking forward to meeting you at the Diagnostic Hall 3, booth # J26 for a discussion on our enzyme solutions for sensitive, …
Tromsø, Norway, 27th October 2022 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 29.3 million (25.2) and an EBITDA of NOK 2.8 million (9.9) for the third quarter of 2022. Highlights from Q3 and first 9 months 2022 ArcticZymes Technologies (AZT) had Q3 sales of NOK 29.3 million growing by 16% (Q3 2021: NOK 25.2 million) and sales for …